NASDAQ$MMSI

Merit Medical Systems Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Merit Medical's financial performance exceeded expectations in Q2 2024, driven by strong momentum and strategic initiatives.

Merit Medical reported a 5.6% increase in revenue to $338.0 million for Q2 2024. The company's GAAP EPS rose by 75.7% to $0.61, while non-GAAP EPS increased by 16.8% to $0.92. Merit Medical also raised its full-year guidance.

  • Reported revenue increased by 5.6% year-over-year, reaching $338.0 million.
  • GAAP operating margin improved to 13.6%, compared to 9.0% in the prior year period.
  • Non-GAAP operating margin increased to 20.1%, compared to 19.1% in the prior year period.
  • GAAP EPS grew by 75.7% to $0.61, and non-GAAP EPS increased by 16.8% to $0.92.

Headline financials

Total Revenue

$338M

Previous: $320M+5.6%
EPS (adj)

$0.92

Previous: $0.81+13.6%
Capital Expenditures

-$22.3M

Previous: -$18.6M-20.2%
Free Cash Flow

$13.4M

Previous: $1.69M+694.4%
Net Income

$35.7M

Previous: $20.2M+76.5%
Operating Income

$45.9M

Previous: $28.8M+59.5%
Gross Profit

$161M

Previous: $153M+5.4%
Cash & Equivalents

$637M

Previous: $72.1M+783.2%
Total Assets

$2.37B

Previous: $1.84B+29.1%
R&D Expense

$20.3M

No prior period
Stock-Based Comp

$7.01M

Previous: $5.58M+25.6%

Revenue & EPS history

Merit Medical · Revenue · Quarterly

$338M

Q2 2024+5.6%vs Q2 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Merit Medical · $9.15M total across 1 segment · Q3 2023

  • Endoscopy
    $9.15M+11.2%

Forward guidance

Merit Medical updated its full-year 2024 financial guidance, reflecting stronger-than-expected organic results and the acquisition of EndoGastric Solutions. The company projects net sales between $1.335 billion and $1.345 billion and non-GAAP earnings per share between $3.27 and $3.35.

Tailwinds

  • Net Sales: $1,335 - $1,345 million (6% - 7% Y/Y growth)
  • Cardiovascular Segment: $1,281 - $1,289 million (5% - 6% Y/Y growth)
  • Endoscopy Segment: $54 - $56 million (45% - 52% Y/Y growth)
  • Non-GAAP Earnings Per Share: $3.27 - $3.35 (15% - 17% Y/Y growth)
  • The updated guidance reflects the EndoGastric Solutions acquisition.

Headwinds

  • Guidance is subject to risks and uncertainties.
  • Material acquisitions, non-recurring transactions, or other factors could impact results.
  • Merit is unable to predict the financial impact of various items which could impact Merit’s future financial results
  • Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.
  • The 2024 financial guidance is excluding material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.1%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+1.8%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+16.5%

Q3 2014

Best reaction

-31.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.2%-6.8%-2.8%
Q4 2025-3.8%-7.2%-16.6%
Q3 2025+5.1%+4.9%+4.3%
Q1 2025-0.1%-0.2%+0.7%
Q4 2024-1.5%+1.0%+1.9%
Q3 2024+2.9%+3.3%+8.3%
Q2 2024+4.0%+5.0%+13.4%
Q1 2024+2.1%+5.2%+7.8%
Q4 2023-5.3%-4.9%-5.9%
Q3 2023+7.7%+7.3%+12.9%
Q2 2023-9.6%-8.3%-16.4%
Q1 2023+4.7%+5.1%+4.3%
Q4 2022+2.8%+1.3%+3.7%
Q3 2022+7.0%+14.6%+19.6%
Q2 2022+6.0%+10.6%+10.0%
Q1 2022-3.7%-4.7%-5.2%
Q4 2021+8.4%+9.3%+5.0%
Q3 2021-1.8%-5.1%-3.5%
Q2 2021+7.6%+3.9%+10.1%
Q1 2021-0.2%+1.4%-5.3%
Q4 2020-1.8%-0.4%+1.9%
Q3 2020+5.2%+1.3%+11.7%
Q2 2020+4.3%-1.9%+11.6%
Q1 2020+9.0%+6.5%+21.4%
Q4 2019+0.4%-9.5%-17.0%
Q3 2019-31.4%-15.5%-7.0%
Q2 2019-24.7%-26.2%-37.2%
Q1 2019-1.9%-4.7%-9.4%
Q4 2018-4.3%-2.1%+1.6%
Q3 2018-4.1%-5.3%-3.5%
Q2 2018+2.8%-3.1%+3.3%
Q1 2018+2.8%+7.5%+18.7%
Q4 2017-2.1%-5.1%-3.3%
Q3 2017-9.7%-11.0%+4.6%
Q2 2017+4.8%+5.5%+4.6%
Q1 2017+8.2%+8.2%+11.6%
Q4 2016+5.9%+4.8%+0.0%
Q3 2016-5.0%-5.0%+5.2%
Q2 2016+6.1%+6.7%+6.5%
Q1 2016+2.5%
Q4 2015-2.8%
Q3 2015-27.3%
Q2 2015+10.7%
Q1 2015+9.5%
Q4 2014+7.7%
Q3 2014+16.5%
Q2 2014-14.4%
Q1 2014-5.4%
Q4 2013+1.2%
Q3 2013+15.4%
Q2 2013+7.6%
Q1 2013-13.9%
Q4 2012-14.7%
Q3 2012-2.8%
Q2 2012-0.5%
Q1 2011-0.7%
Q4 2011-0.7%
Q1 2012+1.1%
Q1 2010-1.6%
Q4 2009-1.6%
Q3 2010-1.1%
Q3 2011-1.1%
Q2 2011+1.6%
Q2 2010+1.6%
Q4 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro